The Association Between Areca-nut Chewing Habit and Metabolic Syndrome

• Conditions: Metabolic Syndrome.; Oral and Esophageal Cancer

• Registration Number: NCT02175524
• Lead Sponsor: Taichung Veterans General Hospital

Brief Summary

The purpose of this study is going to determine the odds ratio of metabolic syndrome (MS), the habit of areca nut chewing, antioxidant, and inflammatory status in oral and esophageal patients. The current study was designed as a case-control study. Patients proved to be oral and esophageal cancer and had the habit of areca nut chewing are defined as case group. Patients proved to be oral and esophageal cancer and did not have the habit of areca nut chewing are defined as control group. The participants' age, blood pressures, and smoking habits will be recorded. Body weight, height, waist, and hip circumferences will be measured. Fasting venous blood samples will be obtained to determine hematological parameters \[i.e., serum creatinine, total cholesterol, triacylglycerol, low density lipoprotein-cholesterol, high density lipoprotein-cholesterol, malondialdehyde, superoxide dismutase, glutathione peroxidase, catalase, and inflammatory markers (C-reactive protein, tumor necrosis factor-alpha, and interleukin-6)\]. Logistic regression analyses are going to perform to examine the relationship between areca nut chewing and MS in this population. If we can make sure the relationship between areca nut chewing and MS, the clinicians and nutritionists can teach people to quit areca nut chewing in order to avoid the possibility of developing metabolic syndrome and cardiovascular disease.

Detailed Description

Not available

Study Timeline

• Study Start: 2014-04
• Status Verified: 2014-06
• Study First Submitted: 2014-06-24
• Study First Submitted QC: 2014-06-24
• Last Update Submitted: 2014-06-24
• Study First Posted: 2014-06-26
• Last Update Posted: 2014-06-26
• Primary Completion: 2017-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

• Patients proved to be oral and esophageal cancer will be recruited.

Exclusion Criteria

• Subjects with diabetes mellitus, liver, renal diseases, or undergoing statin therapy.
• Taking antioxidant vitamins supplements.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Metabolic syndrome	Up to 1 week	Measure blood pressure, blood lipid profiles, fasting glucose, and waist circumferences.

Secondary Outcome Measures

Name	Time	Method
Inflammatory status	Up to 1 week	Measure inflammatory markers: C-reactive protein, Interleukin-6, and tumor necrosis factor-alpha.
Antioxidant activity	Up to 1 week	Antioxidant ability measurements: lipid peroxidation markers (MDA), antioxidant enzymes activities (catalase, glutathione peroxidase, and superoxide dismutase).

Trial Locations

Locations (1)

Taichung Verterans General Hospital; 🇨🇳 Taichung, Taiwan